1 October 2020 - EMA is reminding physicians to use Tecentriq (atezolizumab) only in combination with nab-paclitaxel and not with conventional paclitaxel when treating patients with locally advanced or metastatic triple-negative breast cancer that cannot be surgically removed.

EMA’s advice follows the release of results from a study, IMpassion131, which did not show that combining Tecentriq with conventional paclitaxel in these patients slowed down the progression of the cancer or reduced deaths.

Tecentriq is only authorised for the treatment of triple negative breast cancer in combination with nab-paclitaxel. Nab-paclitaxel is a formulation of paclitaxel that is attached to a protein that affects how the medicine works in the body.

Read EMA press release